This year's charity concert, "Takte gegen Krebs" (Musical bars against cancer) of the National Center for Tumor Diseases (NCT) Heidelberg, will take place on November 3 at the Karlstorbahnhof. Violinist Caroline Adomeit will take musical string leaps from Tartini, Ravel, and Rachmaninov to Celtic-Irish arrangements. Instead of tickets, visitors purchase the musical bars of the compositions. The proceeds benefit innovative and applied cancer research at the NCT Heidelberg - www.nct-takte.de.
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD).
On November 3, it's that time again: the NCT Heidelberg invites you to "Takte gegen Krebs" at the Karlstorbahnhof in Heidelberg's Südstadt. This year's charity concert will feature the German-British violinist Caroline Adomeit. She will undertake musical string leaps that will lead the listeners in a varied way to compositions from six centuries. Carolin Adomeit and pianist Stanislav Rosenberg will play works ranging from Tartini, Ravel and Rachmaninov to Celtic-Irish arrangements that evening.
The guests will individualize the second part of the program as a request concert. Caroline Adomeit has an extraordinary repertoire, ranging from standard violin literature to her own arrangements from film, pop, jazz, musical and international folklore. The multiple award-winning artist has already performed with the Dortmund Philharmonic Orchestra, the Baden-Baden Philharmonic Orchestra, the Hessian State Orchestra Wiesbaden and the Mainz Chamber Orchestra.
Dirk Jäger, Managing Director at the NCT Heidelberg and Medical Director at the Department of Medical Oncology at Heidelberg University Hospital (UKHD), says: "I am already looking forward to the concert evening with Caroline Adomeit with all music enthusiasts. Enjoying her string jumps and supporting the innovative work at the NCT Heidelberg is a wonderful combination."
Traditionally, guests purchase the musical bars instead of tickets. At least one bar is required for one admission. Proceeds from the charity concert will benefit innovative applied cancer research projects at the NCT Heidelberg. Those who purchase more bars than the seats needed will contribute even more to supporting the NCT Heidelberg. Bars are 35 euros each and are available via the website www.nct-takte.de.
Stefan Fröhling, Managing Director at the NCT Heidelberg and Head of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: "We are very pleased and grateful for the contribution that the concertgoers make to our innovative work. Patients are at the center of our work - improving their treatment options is the goal of our research."
Information at a glance
When: Nov. 3, 2023, 7.30 p.m.; admission starts at 7 p.m.
Where: Karlstorbahnhof, Marlene-Dietrich-Platz 3, 69126 Heidelberg
Program: works for violin and grand piano by Guiseppe Tartini, Maurice Ravel, Sergei Rachmaninov, Celtic-Irish arrangements and request concert
Performers: Caroline Adomeit (violin), Stanislav Rosenberg (grand piano)
Ticket order: www.nct-takte.de
Price: 35,00 Euro per musical bar. More than one bar can be purchased per person for the benefit of the NCT Heidelberg
Purpose of the proceeds: Innovative projects of applied cancer research at the NCT Heidelberg
Patronage: Eckart Würzner, Lord Mayor of the City of Heidelberg
Organizer: Heidelberg University Hospital
Contact: Regina Hohmann, Donations NCT Heidelberg, Phone: 06221 56-36146; e-mail: regina.hohmann@nct-heidelberg.de
An image of the press release is available free of charge on the Internet at:
Note on the use of images for press releases
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please quote the copyright "Caroline Adomeit" as photo credit. The image material may only be passed on to third parties after prior consultation with NCT Communications (Phone: +49 6221 42-1755, e-mail: martin.staiger@nct-heidelberg.de). Use for commercial purposes is prohibited.
Contact for the press:
Dr. Martin Staiger
National Center for Tumor Diseases (NCT) Heidelberg
Communication and Events
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 42-1755
E-mail: martin.staiger@nct-heidelberg.de
www.nct-heidelberg.de
Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Strategic Communications and Public Relations
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-2843
Fax: +49 6221 42-2968
E-mail: s.kohlstaedt@dkfz.de
www.dkfz.de
Dr. Stefanie Seltmann
Head of Corporate Communications, Press Spokesperson
Heidelberg University Hospital and Medical Faculty of Heidelberg University
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Phone: +49 6221 56-5052
Fax: +49 6221 56-4544
E-mail: stefanie.seltmann@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de
The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.
German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
- National Center for Tumor Diseases (NCT, 6 sites)
- German Cancer Consortium (DKTK, 8 sites)
- Hopp Children's Cancer Center (KiTZ) Heidelberg
- Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
- National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching
Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds. Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents. The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.